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Abstract. Different substituted diesters of thiazolopyrimidine were prepared by the treatment of 3,4
dihydropyrimidine2-thione with α-haloesters using ethanol under reflux condition affording 71–85% yield. IR,
1HNMR, 13CNMR and elemental analyses were used for the characterization of these compounds. The crys-
tal and molecular structure of one of the product, 5-phenyl-3,7-dimethyl-5H-thiazolo[3,2-a]pyrimidine-2,6-
dicarboxylic acid diethyl ester (3e) was verified by single crystal X-ray diffraction method. The antimicrobial
activity was evaluated against four bacterial strains and one fungal species. Few of the derivatives exhibited
antibacterial and antifungal activities.
Keywords. 3,4-Dihydropyrimidine 2-thione; thiazolopyrimidine; crystal structure; antibacterial
and antifungal activity.
1. Introduction
Pyrimidine derivatives are important class of com-
pounds which display number of pharmacological pro-
perties including antiviral, antitumour, antibacterial and
antihypertensive effects.1–3 In recent years, interest
has also been focused on aza-analogs of 1,4-dihydro-
pyridines such as dihydropyrimidines (DHPMs), which
exhibit a pharmacological profile similar to classical
dihydropyridine calcium channel modulators.4–10
Apart from being well known for their calcium chan-
nel blocking activity, the dihydropyrimidines are also
being explored for their possible therapeutic effects in
treatment of AIDS.11 This is due to the fact that their
particular structure has been found in the natural marine
alkaloids batzelladine A and B, which are the first low-
molecular-weight natural products reported in the lite-
rature to inhibit the binding of HIV gp-120 to CD4
cells, thus opening up a new area in the development
of AIDS therapy.11 Moreover, thiazole derivatives have
acquired a conspicuous significance due to their use
as anti-inflammatory agents. Since the two heterocyclic
moieties thiazole and pyrimidine constitute two active
pharmacophores that are highly active against inflam-
mation and pain, combining the two is expected to have
a synergistic effect on their analgesic properties. This
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idea has been utilized to prepare thiazolopyrimidine
derivatives,12–14 and their pharmacological activity has
been reported.13–16 Thiazolopyrimidine derivatives are
the biosteric analogues of purines and are potentially
bioactive molecules which show anti-inflammatory
activity comparable to that of some standard drugs in
vivo, with no or minimal ulcerogenic effects.17,18 In
continuation of our search of new compounds with
anticipated biological activity, we aimed to obtain new
compounds of the fused thiazole system, with similar
therapeutic properties and other noteworthy chemical
and biological activities.
The synthesis of the compounds was followed by
subsequent spectroscopic analyses using IR, 1H NMR
and 13C NMR techniques to confirm the presence of the
supposed ring systems. The structure of the derivative
5-phenyl-3,7-dimethyl-5H-thiazolo[3,2-a]pyrimidine-2,
6-dicarboxylic acid diethyl ester (3e) was verified by
single crystal X-ray diffraction so that its supramolecu-




All chemicals were obtained from a commercial source
and used without further purification.
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2.2 Analytical methods
Melting points were determined in open capillaries
using Guna melting point apparatus and are uncor-
rected. The IR spectra were recorded on Nicolet Impact
400D FT IR spectrophotometer using KBr pellets. 1H
and 13C NMR were recorded on Bruker 400-MHz FT
NMR spectrometer in CDCl3 and DMSO-d6 with TMS
as internal standard. The reactions and purity of the
products were monitored by TLC silica gel plates.
Mass spectra were recorded on Finnigan MAT (Model
MAT8200) spectrometer and elemental analyses were
carried out using CHNS Elimentar (Vario-micro cube).
2.3 General procedure for the synthesis
of compounds 3(a–i)
A mixture of 3,4 dihyropyrimidine 2-thione (10 mmol)
and ethyl-2-chloroacetoacetate (10 mmol) was refluxed
in dry ethanol (20 ml) for 6 h. Excess of solvent was
distilled off and the solid hydrochloride salt that sepa-
rated was collected by filtration, dissolved in water and
neutralized by aqueous sodium carbonate solution to
get free base. It was filtered, washed with water, dried
and recrystallized from ethyl acetate to afford yellow
compound with good yield 72–85%.
2.3a 5-(4-Methoxy-phenyl)-3,7-dimethyl-5H-thiazolo[3,
2-a]pyrimidine-2,6-dicarboxylic acid diethyl ester (3a):
IR (KBr νmax, cm−1): 2977 (CH), 1703 (C=O), 1600
(C=C), 1496 (C=N). 1H NMR (400 MHz, CDCl3):
δ 1.29 (t, J = 7.2 Hz, 3H,-CH2CH3), 1.33 (t, J =
7.2 Hz, 3H,-CH2CH3), 2.38 (s, 3H, CH3), 2.45 (s, 3H,
CH3), 3.76 (s, 3H, -OCH3), 4.15 (q, J = 7.2 Hz, 2H,
CH2CH3), 4.25 (q, J = 7.2 Hz, 2H, CH2CH3), 6.10 (s,
1H, CH), 6.81–7.26 (m, 4H, ArH). 13C NMR (CDCl3)δ:
12.65, 14.22, 14.35, 23.59, 55.24, 57.24, 60.04, 61.43,
102.58, 114.15, 127.91, 129.1, 134.69, 145.11, 154.67,
159.62, 161.17, 163.72, 166.51. Mass (m/z):416 M+,
401, 371, 387, 343 (base peak), 309, 253; CHNS found
(calc)%: C 60.56 (60.42), H 5.81 (4.76), N 6.73 (6.83),
S 7.70 (7.59).
2.3b 5-(3,4-Dimethoxy-phenyl)-3,7-dimethyl-5H-thiazolo
[3,2-a]pyrimidine-2,6-dicarboxylic acid diethyl ester
(3b): IR (KBr νmax, cm−1): 2984 (CH), 1709 (C=0),
1602 (C=C), 1501 (C=N). 1H NMR (300 MHz,
CDCl3): δ 1.27 (t, J = 7.2 Hz, 3H,-CH2CH3), 1.34 (t,
J = 7.2 Hz, 3H,-CH2CH3), 2.38 (s, 3H, CH3), 2.46 (s,
3H, CH3), 3.83 (s, 3H, -OCH3), 3.85 (s, 3H, -OCH3),
4.15 (q, J = 7.2 Hz, 2H, CH2CH3), 4.25 (q, J = 7.2 Hz,
2H, CH2CH3), 6.11 (s, 1H, CH), 6.74–7.26 (m, 3H,
ArH). 13C NMR (CDCl3) δ: 12.64, 14.22, 14.35,
55.24, 55.86, 57.22, 60.03, 61.46, 102.48, 106.89,
109.60, 111.04, 114.14, 118.81, 127.90, 134.73,
145.12, 149.16, 154.73, 159.61, 161.17, 163.81,
166.53, 166.63. CHNS found (calc)%: C 59.18 (59.04),
H 5.87 (5.62), N 6.27 (6.32), S 7.18 (7.31).
2.3c 5-(4-Hydroxy-phenyl)-3,7-dimethyl-5H-thiazolo[3,
2-a]pyrimidine-2,6-dicarboxylic acid diethyl ester
(3c): IR (KBr νmax, cm−1) 3342 (OH), 2992 (CH),
1707 (C=O), 1610 (C=C), 1496 (C=N). 1H NMR
(300 MHz, CDCl3): δ 1.28 (t, J = 7.2 Hz, 3H,-
CH2CH3), 1.31 (t, J = 7.2 Hz, 3H,-CH2CH3), 2.38 (s,
3H, CH3), 2.46 (s, 3H, CH3), 4.16 (q, J = 7.2 Hz, 2H,
CH2CH3), 4.24 (q, J = 7.2 Hz, 2H, CH2CH3), 6.10 (s,
1H, CH), 6.70–7.12 (m, 4H, ArH), 7.27 (s, 1H, -OH).
CHNS found (calc)%: C 59.69 (59.55), H 5.51 (5.35),
N 6.96 (7.12), S 7.97 (7.67).
2.3d 3,7-Dimethyl-5-thiophen-2-yl-5H-thiazolo[3,2-a]
pyrimidine-2,6-dicarboxylic acid diethyl ester (3d):
IR (KBr νmax, cm−1): 2976 (CH), 1705, 1610 (C=O),
1506 (C=N). 1H NMR (300 MHz, CDCl3): δ 1.32 (t,
J = 7.2 Hz, 3H,–CH2CH3), 1.36 (t, J = 7.2 Hz, 3H,
–CH2CH3), 2.44 (s, 3H, CH3), 2.58 (s, 3H, CH3), 4.23
(q, J = 7.2 Hz, 2H, CH2CH3), 4.31 (q, J = 7.2 Hz, 2H,
CH2CH3), 6.5 (s, 1H, CH), 6.88–7.26 (m, 3H, ArH).
CHNS found (calc)%: C 55.08 (55.21), H 5.14 (4.97),
N 7.14 (7.22), S 16.34 (16.23).
2.3e 5-phenyl-3,7-dimethyl-5H-thiazolo[3,2-a]pyrimidine-2,
6-dicarboxylic acid diethyl ester (3e): IR (KBr νmax,
cm−1): 2976 (CH), 1705 (C=O), 1610 (C=C), 1506
(C=N). 1H NMR (300 MHz, CDCl3): δ 1.28 (t,
J = 7.2 Hz, 3H,-CH2CH3), 1.32 (t, J = 7.2 Hz, 3H,
-CH2CH3), 2.38 (s, 3H, CH3), 2.46 (s, 3H, CH3), 4.17
(q, J = 7.2 Hz, 2H, CH2CH3), 4.27 (q, J = 7.2 Hz, 2H,
CH2CH3), 6.09 (s, 1H, CH), 6.79–6.84 (m, 5H, ArH).
CHNS found (calc)%: C 62.16 (62.47), H 5.74 (5.72),
N 7.25 (7.32), S 8.30 (8.13).
2.3f 5-(3-Methoxy-phenyl)-3,7-dimethyl-5H-thiazolo[3,
2-a]pyrimidine-2,6-dicarboxylic acid 2-ethyl ester 6-
methyl ester (3f): IR (KBr νmax, cm−1): 2992 (CH),
1709 (C=O), 1620 (C=C), 1533 (C=N). 1H NMR
(300 MHz, CDCl3): 1.32 (t, J = 7.2 Hz, 3H,-CH2CH3),
2.37 (s, 3H, CH3), 2.44 (s, 3H, CH3), 3.76 (s, 3H,
-OCH3), 3.82 (s, 3H, -OCH3), 4.23 (q, J = 7.2 Hz, 2H,
CH2CH3), 6.16 (s, 1H, CH), 6.78–7.26 (m, 4H, ArH).
CHNS found (calc)%: C 59.69 (59.56), H 5.51 (5.33),
N 6.96 (7.07), S 7.97 (8.04).
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2.3g 3,7-Dimethyl-5-naphthalen-1-yl-5H-thiazolo[3,2-a]
pyrimidine-2,6-dicarboxylic acid 2-ethyl ester 6-
methyl ester (3g): IR (KBr νmax, cm−1): 2996(CH),
1712(C=O), 1601(C=C), 1496(C=N). 1H NMR
(300 MHz, CDCl3): 1.28 (t, J = 7.2 Hz, 3H,-CH2CH3),
2.35 (s, 3H, CH3), 2.51 (s, 3H, CH3), 3.82 (s, 3H,
-OCH3), 4.22 (q, J = 7.2 Hz, 2H, CH2CH3), 6.89
(s, 1H, CH), 7.42–8.45 (m, 7H, ArH). CHNS found
(calc)%: C 65.38 (65.53), H 5.25 (5.19), N 6.63 (6.72),
S 7.59 (7.71).
2.3h 3,7-Dimethyl-5-thiophen-2-yl-5H-thiazolo[3,2-a]
pyrimidine-2,6-dicarboxylic acid 2-ethyl ester 6-
methyl ester (3h): IR (KBr νmax, cm−1): 2992 (CH),
1710 (C=O), 1609 (C=C), 1502 (C=N). 1H NMR
(400 MHz, CDCl3): 1.36 (t, J = 7.2 Hz, 3H,-CH2CH3),
2.39 (s, 3H, CH3), 2.55 (s, 3H, CH3), 3.76 (s, 3H,
OCH3), 4.29 (q, J = 7.2 Hz, 2H, CH2CH3), 6.45(s, 1H,
CH), 6.86–7.26 (m, 3H, ArH). 13C NMR (CDCl3) δ:
12.46, 14.24, 14.40, 23.46, 51.23, 52.82, 60.25, 61.57,
124.67, 125.68, 126.73, 1444.28, 144.50, 161.14,
166.58. CHNS found (calc)%: C 53.95 (54.05), H 4.79
(4.63), N 7.40 (7.29), S 16.95 (16.76).
2.3i 5-(4-Hydroxy-3-methoxy-phenyl)-3,7-dimethyl-5H-
thiazolo[3,2-a]pyrimidine-2,6-dicarboxylic acid 2-ethyl
ester 6-methyl ester (3i): IR (KBr νmax, cm−1): 3379
(OH), 2993 (CH), 1715 (C=O), 1611 (C=C), 1506
(C=N). 1H NMR (400 MHz, CDCl3): 1.31 (t, J =
7.2 Hz, 3H,-CH2CH3), 2.38 (s, 3H, CH3), 2.46 (s,
3H, CH3), 3.71 (s, 3H, -OCH3) 3.86 (s, 3H, -OCH3),
4.27 (q, J = 7.2 Hz, 2H, CH2CH3), 6.09 (s, 1H, CH),
6.79–6.84 (m, 3H, ArH), 7.26 (s, 1H, OH). 13C NMR
(CDCl3) δ: 12.64, 14.20, 14.37, 23.49, 51.10, 55.19,
57.54, 60.10, 61.49, 102.42, 102.61, 107.14, 108.81,
110.94, 114.32, 119.50, 134.29, 145.08, 146.91,
161.11, 163.87, 166.97. CHNS found (calc)%: C 57.40
(57.31), H 5.30 (5.45), N 6.69 (6.48), S 7.66 (7.43).
2.4 General procedure for the synthesis
of compounds 5(a–m)
A mixture of 3,4 dihyropyrimidine 2-thione (10 mmol)
and ethyl-4-chloroacetoacetate (10 mmol) was refluxed
in dry ethanol (20 ml) for 12 h. Excess of solvent was
distilled off and the solid hydrochloride salt that sepa-
rated was collected by filtration, dissolved in water and
neutralized by aqueous sodium carbonate solution to
get free base. It was filtered, washed with water, dried
and recrystallized from ethyl acetate to afford yellow
compound with good yield 70–85%.
2.4a 3-Ethoxycarbonylmethyl-7-methyl-5-phenyl-5H-
thiazolo[3,2-a]pyrimidine-6-carboxylic acid ethyl
ester (5a): IR (KBr νmax, cm−1): 3099, 2987 (CH),
1730, 1660 (C=O), 1479 (C=N). 1H NMR (400 MHz,
CDCl3): δ 1.18 (t, J = 7.2 Hz, 3H,-CH2CH3), 1.28 (t,
J = 7.2 Hz, 3H, -CH2CH3), 2.37 (s, 3H, CH3), 3.35
(s, 2H, CH2), 4.11 (q, J = 7.2 Hz, 2H, CH2CH3), 4.17
(q, J = 7.2 Hz, 2H, CH2CH3), 6.21 (s, 1H, CH), 6.23
(s, 1H, S-CH), 7.24–7.32 (m, 5H, ArH). 13C NMR
(CDCl3) δ: 14.05, 14.35, 23.74, 33.61, 57.91, 59.75,
61.83, 100.5, 103.66, 126.39, 128.18, 128.37, 128.68,
128.82, 131.63, 142.83, 155.55, 166.29, 166.60,
167.73. CHNS found (calc)%: C 62.16 (61.98), H 5.74
(5.69), N 7.25 (7.13), S 8.30 (8.27).
2.4b 3-Ethoxycarbonylmethyl-5-(3-methoxy-phenyl)-
7-methyl-5H-thiazolo[3,2-a]pyrimidine-6-carboxylic
acid ethyl ester (5b): IR (KBr νmax, cm−1): 3095,
2974 (CH), 1732, 1650 (C=O), 1484 (C=N), 1H
NMR (400 MHz, DMSO): δ 1.24 (t, J = 7.2 Hz, 3H,
-CH2CH3), 1.26 (t, J = 7.2 Hz, 3H,-CH2CH3), 2.38 (s,
3H, CH3), 3.32 (s, 2H, CH2), 3.81 (s, 3H, -OCH3) 4.12
(q, J = 7.2 Hz, 2H, CH2CH3), 4.19 (q, J = 7.2 Hz, 2H,
CH2CH3), 6.16 (s, 1H, CH), 6.28 (s, 1H, S-CH), 6.98–
7.26 (m, 4H, ArH). CHNS found (calc)%: C 60.56
(60.45), H 5.81 (5.99), N 6.73 (6.67), S 7.70 (7.81).
2.4c 3-Ethoxycarbonylmethyl-5-(4-methoxy-phenyl)-
7-methyl-5H-thiazolo[3,2-a]pyrimidine-6-carboxylic
acid ethyl ester (5c): IR (KBr νmax, cm−1): 3082,
2991 (CH), 1726, 1658 (C=O), 1481 (C=N). 1H
NMR (300 MHz, CDCl3): δ 1.29 (t, J = 7.2 Hz, 3H,
-CH2CH3), 1.33 (t, J = 7.2 Hz, 3H,-CH2CH3), 2.37 (s,
3H, CH3), 3.26 (s, 2H, CH2) 3.79 (s, 3H, -OCH3), 4.16
(q, J = 7.2 Hz, 2H, CH2CH3), 4.25 (q, J = 7.2 Hz, 2H,
CH2CH3), 6.10 (s, 1H, CH), 6.29 (s, 1H, S-CH), 6.81–
7.22 (m, 4H, ArH). CHNS found (calc)%: C 60.56
(60.43), H 5.81 (5.93), N 6.73 (6.71), S 7.70 (7.87).
2.4d 5-(3,4-Dimethoxy-phenyl)-3-ethoxycarbonylmethyl-
7-methyl-5H-thiazolo[3,2-a]pyrimidine-6-carboxylic acid
ethyl ester (5d): IR (KBr νmax, cm−1): 3072, 2992
(CH), 1729, 1654 (C=O), 1488 (C=N). 1H NMR
(300 MHz, CDCl3): δ 1.31 (t, J = 7.2 Hz, 3H,
-CH2CH3), 1.37 (t, J = 7.2 Hz, 3H,-CH2CH3), 2.38 (s,
3H, CH3), 3.46 (s, 2H, CH2), 3.83 (s, 3H, -OCH3), 3.90
(s, 3H, -OCH3), 4.15 (q, J = 7.2 Hz, 2H, CH2CH3),
4.25 (q, J = 7.2 Hz, 2H, CH2CH3), 6.11 (s, 1H, CH),
6.21 (s, 1H, S-CH), 6.74–7.26 (m, 3H, ArH). CHNS
found (calc)%: C 59.18(59.22), H 5.87 (5.93), N 6.27
(6.37), S 7.18 (7.14).
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2.4e 3-Ethoxycarbonylmethyl-5-(4-hydroxy-phenyl)-
7-methyl-5H-thiazolo[3,2-a]pyrimidine-6-carboxylic
acid ethyl ester (5e): IR (KBr νmax, cm−1): 3344(OH),
3021, 2981 (CH), 1728, 1662 (C=O), 1472 (C=N). 1H
NMR (400 MHz, DMSO): δ 1.16 (t, J = 7.2 Hz, 3H,
-CH2CH3), 1.21 (t, J = 7.2 Hz, 3H,-CH2CH3), 2.23 (s,
3H, CH3), 3.29 (s, 2H, CH2), 4.00 (q, J = 7.2 Hz, 2H,
CH2CH3), 4.10 (q, J = 7.2 Hz, 2H, CH2CH3), 5.96 (s,
1H, CH), 6.07 (s, 1H, S-CH), 6.66–7.05 (m, 4H, ArH),
9.50 (s, 1H, -OH). 13C NMR (DMSO) δ: 13.89, 14.12,
23.18, 32.77, 56.53, 59.04, 61.07, 110.02, 104.93,
115.34, 127.32, 127.61, 131.86, 133.71, 154.16,
157.36, 165.32, 165.59, 168.05. CHNS found (calc)%:




ethyl ester (5f): IR (KBr νmax, cm−1): 3056, 2990
(CH), 1725, 1667 (C=O), 1481 (C=N). 1H NMR
(300 MHz, CDCl3): δ 1.14 (t, J = 7.2 Hz, 3H,
-CH2CH3), 1.27 (t, J = 7.2 Hz, 3H,-CH2CH3), 2.51 (s,
3H, CH3), 3.28 (s, 2H, CH2), 4.06 (q, J = 7.2 Hz, 2H,
CH2CH3), 4.26 (q, J = 7.2 Hz, 2H, CH2CH3), 6.81 (S,
1H, CH), 7.05 (s, 1H, S-CH), 7.47–8.32 (m, 7H, ArH).
CHNS found (calc)%: C 66.03 (66.21), H 5.54 (5.66),
N 6.42 (6.29), S 7.35 (7.54).
2.4g 3-Ethoxycarbonylmethyl-7-methyl-5-thiophen-
2-yl-5H-thiazolo[3,2-a]pyrimidine-6-carboxylic acid
ethyl ester (5g): IR (KBr νmax, cm−1): 3082, 2982
(CH), 1725, 1655 (C=O), 1488 (C=N). 1H NMR
(300 MHz, CDCl3): δ 1.29 (t, J = 7.2 Hz, 3H,
-CH2CH3), 1.33 (t, J = 7.2 Hz, 3H,-CH2CH3), 2.58 (s,
3H, CH3), 3.28 (s, 2H, CH2), 4.20 (q, J = 7.2 Hz, 2H,
CH2CH3), 4.29 (q, J = 7.2 Hz, 2H, CH2CH3), 6.38 (s,
1H, CH), 6.50 (s, 1H, S-CH), 6.91–7.24 (m, 3H, ArH).
CHNS found (calc)%: C 55.08 (55.14), H 5.14 (5.17),
N 7.14 (6.97), S 16.34 (16.47).
2.4h 3-Ethoxycarbonylmethyl-5-(4-hydroxy-3-methoxy-
phenyl)-7-methyl-5H-thiazolo[3,2-a]pyrimidine-6-
carboxylic acid ethyl ester (5h): IR (KBr νmax, cm−1):
3387(OH), 3066, 2976 (CH), 1730, 1653 (C=O),
1484 (C=N). 1H NMR (400 MHz, DMSO): 1.18 (t,
J = 7.2 Hz, 3H,-CH2CH3), 1.23 (t, J = 7.2 Hz, 3H,-
CH2CH3), 2.47 (s, 3H, CH3), 3.38 (s, 2H, CH2), 3.83
(s, 3H, -OCH3), 4.19 (q, J = 7.2 Hz, 2H, CH2CH3),
4.25 (q, J = 7.2 Hz, 2H, CH2CH3), 5.85 (s, 1H, CH),
6.10 (s, 1H, S-CH), 6.74–6.85 (m, 3H, ArH), 7.77 (s,
1H, OH). 13C NMR (DMSO) δ: 13.87, 14.18, 23.17,
32.81, 55.46, 56.73, 59.06, 60.64, 99.87, 104.89,
110.17, 115.65, 118.60, 131.97, 134.19, 146.64,
147.28, 154.29, 165.39, 165.65, 168.1. CHNS found




methyl ester (5i): IR (KBr νmax, cm−1): 3021, 2981
(CH), 1728, 1662 (C=O), 1472 (C=N). 1H NMR
(400 MHz, DMSO): δ 1.21 (t, J = 7.2 Hz, 3H,
-CH2CH3), 2.38 (s, 3H, CH3), 3.29 (s, 2H, CH2), 3.76
(s, 3H, -OCH3), 3.92 (s, 3H, -OCH3), 4.18 (q, J =
7.2 Hz, 2H, CH2CH3), 6.16 (s, 1H, CH), 6.28 (s, 1H,
SH), 6.79–7.28 (m, 4H, ArH). 13C NMR (DMSO) δ:
13.96, 23.07, 32.08, 55.00, 56.71, 57.09, 61.32,102.13,
105.17, 112.35, 113.25, 118.21, 129.96, 130.25,
143.70, 154.05, 159.33, 160.46, 162.63, 165.36. CHNS
found (calc)%: C 59.69 (59.88), H 5.51 (5.53), N 6.96
(7.04), S 7.97 (7.71).
2.4j 3-Ethoxycarbonylmethyl-5-(4-hydroxy-phenyl)-7-
methyl-5H-thiazolo[3,2-a]pyrimidine-6-carboxylic acid
methyl ester (5j): IR (KBr νmax, cm−1): 3348(OH),
3056, 2987 (CH), 1732, 1659 (C=O), 1486 (C=N). 1H
NMR (400 MHz, DMSO): δ 1.19 (t, J = 7.2 Hz, 3H,
CH2CH3), 2.46 (s, 3H, CH3), 3.29 (s, 2H, CH2), 3.84(s,
3H, OCH3), 4.22 (q, J = 7.2 Hz, 2H, CH2CH3), 6.10 (s,
1H, CH), 6.20 (s, 1H, SCH), 6.76–7.19 (m, 4H, ArH),
8.65 (s, 1H, -OH). CHNS found (calc)%: C 58.75
(58.71), H 5.19 (5.33), N 7.21 (7.10), S 8.26 (8.42).
2.4k 3-Ethoxycarbonylmethyl-7-methyl-5-naphthalen-
1-yl-5H-thiazolo[3,2-a]pyrimidine-6-carboxylic acid
methyl ester (5k): IR (KBr νmax, cm−1): 3031, 2998
(CH), 1727, 1653 (C=O), 1483 (C=N). 1H NMR
(300 MHz, CDCl3): δ 1.17 (t, J = 7.2 Hz, 3H,
-CH2CH3), 2.50 (s, 3H, CH3), 3.31 (s, 2H, CH2),
3.83(s, 3H, OCH3), 4.20 (q, J = 7.2 Hz, 2H, CH2CH3),
6.80 (s, 1H, CH), 6.85 (s, 1H, SCH), 7.37–8.42 (m, 7H,
ArH). CHNS found (calc)%: C 65.38 (65.27), H 5.25
(5.15), N 6.63 (6.71), S 7.59 (7.74).
2.4l 3-Ethoxycarbonylmethyl-7-methyl-5-thiophen-2-
yl-5H-thiazolo[3,2-a]pyrimidine-6-carboxylic acid methyl
ester (5l): IR (KBr νmax, cm−1): 3044, 2995 (CH),
1735, 1654 (C=O), 1489 (C=N). 1H NMR (300 MHz,
CDCl3): δ 1.31 (t, J = 7.2 Hz, 3H,-CH2CH3), 2.57 (s,
3H, CH3), 3.31 (s, 2H, CH2), 3.78 (s, 3H, -OCH3), 4.31
(q, J = 7.2 Hz, 2H, CH2CH3), 6.38 (s, 1H, CH), 6.50
(s, 1H, SCH), 6.88–7.25 (m, 3H, ArH). CHNS found
























Scheme 1. Synthesis of 5-(aryl substituted)-3,7-dimethyl-5H-thiazolo[3,2-a]pyrimidine- 2,
6-dicarboxylic acid diester.




carboxylic acid methyl ester (5m): IR (KBr): 3392
(OH), 3033, 2987 (CH), 1725, 1666 (C=O), 1481
(C=N). 1H NMR (400 MHz, DMSO): δ 1.30 (t, J =
7.2 Hz, 3H,-CH2CH3), 2.32 (s, 3H, CH3), 3.37 (s, 2H,
-CH2), 3.82 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 4.29
(q, J = 7.2 Hz, 2H, CH2CH3), 5.85 (s, 1H, CH), 6.09
(s,1H, SCH), 6.82–6.97 (m, 3H, ArH), 8.19 (s, 1H,
OH). CHNS found (calc)%: C 57.40 (57.22), H 5.30
(5.43), N 6.69 (6.75), S 7.66 (7.49).
2.5 Crystallography
Yellow coloured single crystal of compound 3e was
obtained by slow evaporation of 1:1 mixture of ethyl
acetate and methanol solvents. The X-ray diffrac-
tion data for the compound 3e was collected on
a Bruker Smart CCD Area Detector, using MoKα
(λ = 0.71073Å) radiation. Intensity data were col-
lected up to a maximum of 23◦ in the ω– scan
mode. The data were reduced using SAINT-PLUS.19
The structure was solved by direct methods using
SHELXS9720 and refined by difference Fourier synthe-
ses using SHELXL97.20 The positional and anisotropic
displacement parameters of all non-hydrogen atoms
were included in the full-matrix least-square refine-
ment. A total of 9700 reflections were collected, result-
ing in 3348 [R(int) = 0.0467] independent reflections
of which the number of reflections satisfying I>2σ (I)
criteria was 2514. The R factor for observed data finally
converged to R = 0.0541 with wR2 = 0.1356. Molecu-
lar diagrams were generated using ORTEP.21 The
mean plane calculation was done using the program
PARST.22
The CIF file was deposited at the Cambridge Crys-
tallographic Data Centre, The deposition number is
CCDC-841973
2.6 Antimicrobial activity
Antibacterial activities of the synthesized compounds
3(a–i) were tested against the following standard bacte-
rial strains: Bacillus subtilis (MTCC 121), Staphylococ-
cus aureus (7443), Escherichia coli (7410) and Pseu-
domonas aeruginosa (MTCC 7903) by Paper disc dif-
fusion method.23,24 The standard strains were procured
from the (MTCC) and the pathological strains were
produced. The sterile medium (Nutrient Agar medium,
15 mL) in each Petri plates was uniformly smeared
with cultures of Gram +ve and Gram -ve bacteria.
Sterile discs of 10 mm diameter (Hi-Media) were made
in each of the Petri plates, to which 50 μL (1 mg/mL
i.e., 50 μg/disc) of the different test compounds were
added. The treatments also included 50 μL of ethyl
acetate and gentamicin as negative and positive con-
trol for comparison. For each treatment, three replicates
were maintained. The plates were incubated at 37◦C for
24 h and the size of the resulting zone of inhibition, if
any, was determined. The data were subjected to ana-
lysis of variance (ANOVA). The results of the anti-





















Scheme 2. Synthesis of 3-Ethoxycarbonylmethyl-5-(substituted aryl)-7-methyl-5H-
thiazolo[3,2-a]pyrimidine-6-carboxylic acid ester.
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3. Result and discussion
3.1 Synthesis
The parent compound (dihydropyrimidine derivatives)
1 was obtained on refluxing the substituted aryl aldehy-
des, thiourea and ethyl/methyl acetoacetate in ethanol
for 7–9h in the presence of catalytic amount of concen-
trated hydrochloric acid. The reaction mixture was kept
overnight and the precipitate obtained was filtered and
the compound was recrystallized with ethanol in good
yield.25
The treatment of 1 with α-haloester in ethanol under
reflux for about 6 h and 12 h afforded 3(a–i) as shown
in scheme 1 and 5(a–m) as shown in scheme 2 respec-
tively. The proposed mechanism for the above reaction
is given in scheme 3. Yields of these one pot protocol
reactions following recrystallization from ethanol were
in the order of 71–85% as shown in table 1.
The IR spectra of compounds 3(a–i) and 5(a–m)
showed the absence of the sharp absorption peak at
3200–3400 cm−1, which is the characteristic absorp-
tion of NH group of starting material. This marks the








































nucleophilic attack of 
sulphur on carbon bearing 
chlorine
attack of imino-nirogen 
to the carbonyl carbon
dehydrationneutralisation
For scheme 1: R1=Me or Et, R2=Me & R3=COOEt
For scheme 2: R1=Me or Et, R2=CH2COOEt & R3=H
Scheme 3. Mechanism for the synthesis of compounds (3a–3i) and (5a–5m).
Table 1. Physical and analytical data of the compounds (3a–3i) and (5a–5m).
Products Ar R1 Yield (%) m.p. (◦C) Mol. formula
3a 4-OCH3C6H4 OEt 81 117–118 C21H24N2O5S
3b 4-OCH3 3-OCH3C6H3 OEt 83 109–110 C22H26N2O6S
3c 4-OHC6H4 OEt 78 117–118 C20H22N2O5S
3d C4H3S (Thienyl) OEt 76 114–115 C18H20N2O4S2
3e C6H5 OEt 85 132–133 C20H22N2O4S
3f 3-OCH3C6H4 OMe 83 112–113 C20H22N2O5S
3g α-napthyl OMe 72 119–120 C23H22N2O4S
3h C4H3S (Thienyl) OMe 76 117–118 C17H18N2O4S2
3i 4-OH 3-OCH3C6H3 OMe 75 115–116 C20H22N2O6S
5a C6H5 OEt 74 134–135 C20H22N2O4S
5b 3-OCH3C6H4 OEt 82 141–142 C21H24N2O5S
5c 4-OCH3C6H4 OEt 70 133–134 C21H24N2O5S
5d 4-OCH3 3-OCH3C6H3 OEt 73 138–139 C22H26N2O6S
5e 4-OHC6H4 OEt 71 134–135 C20H22N2O5S
5f α-napthyl OEt 72 135–136 C24H24N2O4S
5g C4H3S (Thienyl) OEt 74 133–134 C18H20N2O4S2
5h 4-OH 3-OCH3C6H3 OEt 78 128–129 C21H24N2O6S
5i 3-OCH3C6H4 OMe 85 104–105 C20H22N2O5S
5j 4-OHC6H4 OMe 75 112–113 C19H20N2O5S
5k α-napthyl OMe 72 106–107 C23H22N2O4S
5l C4H3S (Thienyl) OMe 79 111–112 C17H18N2O4S2
5m 4-OH 3-OCH3C6H3 OMe 75 108–109 C20H22N2O6S2
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Table 2. Crystal data and structure refinement for compound 3e.














Calculated density (mg/m3) 1.344
Absorption coefficient (0.198 mm−1)
F(000) 816
Crystal size 0.40 mm × 0.35 mm × 0.30 mm




Reflections collected/unique 9700/3348 [R(int) = 0.0467]
Completeness to theta 24.99 99.8%
Refinement method Full-matrix least-squares on F2
Data/restraints/parameters 3348/0/248
Goodness-of-fit on F2 1.096
Final R indices [I > 2sigma(I)] R1 = 0.0541, wR2 = 0.1356
R indices (all data) R1 = 0.0740, wR2 = 0.1633
Largest diff. peak and hole (e Å´−3) 0.709 and −0.335
Further confirmation of the products 3(a–i) was done
from 1H NMR spectra, where the appearance of addi-
tional triplet signal at 1.30–1.35 ppm, quartet signal at
4.2–4.3 ppm and singlet at 2.45 ppm corresponds to the
formation of new CH3, CH2 and CH3 groups, respec-
tively. Downfield shift of the 5H proton to 6.1 ppm
is a further confirmatory evidence for the product for-
mation. In support of the formation of the products
Table 3. Non-bonded interactions and possible hydrogen
bonds (Å, ◦) for compound 3e.
D—H· · ·A D—H H· · ·A D· · ·A D—H· · ·A
C1-H1C. . . O3i 0.960(3) 2.564(2) 3.510(3) 168.57
C11-H11. . . N1ii 0.930(3) 2.637(2) 3.507(4) 156.1
C7-H7Aπ . . . HI4ig 0.969(2) 3.282(2) 4.164(4) 152.1
(D-donor; A-acceptor; H-hydrogen)
Symmetry code: (i) x − 1/2,−y + 1/2 + 1,+z − 1/2
(ii) x − 1/2,−y + 1/2 + 1,+z + 1/2
(ii) x + 1/2, 3/2 − y, z + 1/2
5(a–m) by 1H NMR spectra, the triplet signal at 1.30–
1.35 ppm, quartet signal at 4.2–4.3 ppm, singlet at
2.45 ppm corresponds to the formation of additional
Figure 1. Ortep view of compound 3e, showing 50% proba-
bility ellipsoids and the atom numbering scheme.
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Figure 2. A unit cell packing of the title compound show-
ing intermolecular interactions with dotted lines. H-atoms
not involved in hydrogen bonding have been excluded.
CH3, CH2 and CH2 groups respectively. Appearance of
singlet at 6.2 ppm confirms the 1H of thiazole.
3.2 Crystal structure analysis
Summary of the crystallographic data and other struc-
ture refinement parameters of the compound 3e are
shown in table 2. Table 3 shows the respective hydrogen
bond interactions of the compound. The ORTEP view
of the molecule with atomic labelling (thermal ellip-
soids drawn at 50% probability) is shown in figure 1.
Figure 2 shows the packing of molecules in the crystal
structure.
In the compound 3e the thiazolopyrimidine ring
is substituted with the aryl ring at C4 chiral carbon
atom and is positioned axially to the dihydropyrimi-
dine ring,26 whereas carboxylic acid ethyl ester and
the methyl, groups are on either side of the ring. The
dihedral angle between the planes of the aryl and thia-
zolopyrimidine rings is 86.49◦. The 4-aryl substituent
(methoxy group) adopts a synperiplanar configuration
with respect to C4–H4 bond. In 3e, the central pyrimi-
dine ring with a chiral C4 atom at the point of substitu-
tion of a benzene ring (C9–C14) is significantly puck-
ered and adopts a conformation which is best described
as an intermediate between a boat and a screw boat
form.27 The ring puckering parameters28 for the pyrim-
idine ring are Q (2) = 0.2217(3) Å, ϕ (2) = −8.02(7)◦
and q = 117.06(6)◦, respectively.
The crystal structure is primarily stabilized by some
interesting features that comprise intermolecular C–
H. . . O and C–H. . . N interactions. A strong intermolecu-
lar C–H. . . O interaction results in chain of molecule
along b axis. On the other hand a strong C–H. . . N
hydrogen bond results in forming bridge between the
two chains of molecules.The molecular packing is fur-
ther stabilized by π-π stacking interactions between the
thiazolopyrimidine rings as the C5–C17 (-x, 1-y, -z) is
disposed at a distance of 3.518(3) Å. In addition, π-
ring interactions of the type C–H. . . Cg (Cg being the
centroid of the rings) are also observed in the crystal
structure, table 2.
Table 4. Inhibition zone diameter (mm) of synthesized compounds against tested bacterial strains by paper disc diffusion
method.
Gram-positive bacteria Gram-negative bacteria Fungi
Bacillus Staphylococcus Pseudomonas Candida
Compounds subtilis aureus Escherichia coli aeruginosa albicans
3a – – 15.0 ± 1.00 – 15.66 ± 0.56
3b – – – – –
3c – 18.00 ± 1.00 – – –
3d – – – – –
3e – 19.66 ± 0.56 – – 16.00 ± 1.0
3f – – – – –
3g – – – – 13.66 ± 1.52
3h – – – –
3i – – –
Gentamicin (10 μg/disc) 25 26 30 20 ND
Nystatin (10 μg/disc) ND ND ND ND 20
Note: “–” Not active, “ND” – Not determined.
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3.3 Antimicrobial evaluation
The antimicrobial activity was performed using disc
diffusion method with different stains of bacteria and
fungi. The results with test compounds 3(a–i) indicate
some degrees of antimicrobial activity. Gentamicin was
used as a reference to evaluate the potency of tested
compounds. Compounds 3a, 3c, 3e and 3g showed
moderate antimicrobial activity, while compounds 3b,
3d, 3f, 3h and 3i did not show any activity against the
tested microorganisms. The results of the antimicrobial
activity is given in table 4.
4. Conclusion
The present work reports the synthesis of diesters of
thiazolopyimidine derivatives. The formation of the
thiazolopyrimidine moiety was confirmed by analyt-
ical data. The investigation of antimicrobial screen-
ing reveals that the compounds 3a, 3c, 3e and 3g
have moderate antimicrobial activities against Staphy-
lococcus aureus, Escherichia coli and Candida albi-
cans comparable to the standard Gentamicin and Nys-
tatin. Additionally, X-ray analysis was carried out for
one of the derivative in order to establish supramolecu-
lar assembly with the specific aim of assessing various
weak interactions including CH. . . O, CH. . . N, π . . . π
and CH. . . π that control the architecture of organic
solids.
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